Last Updated: June 26, 2026

CLINICAL TRIALS PROFILE FOR PROVOCHOLINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PROVOCHOLINE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01064245 ↗ Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests Active, not recruiting Queen's University (William M Spear / Start Memorial Fund) N/A 2010-02-01 Cough is a common, disruptive and at times disabling symptom which often prompts patients to seek medical attention. Determining the cause(s) of chronic cough can be challenging, and costly. Asthma and other airway disorders are among the most common causes of chronic cough; and cough can be the sole symptom of asthma. Little is known about why some patients with asthma primarily cough and do not develop the other symptoms of asthma such as shortness of breath or wheeze. Improved understanding of the reasons for these different manifestations may lead to new and more effective treatment strategies. We have notices differences in pressure measurements inside the chest in patients who mostly cough during induced bronchoconstriction, which might be part of the explanation for varying symptoms. This study will compare lung mechanical responses during methacholine and mannitol-induced induced airway narrowing between typical asthma, cough variant asthma (CVA) and an airway inflammatory disorder that is not asthma.The purpose of this research is to explore the pathophysiology and sensory-mechanics of cough in individuals with asthma, CVA and methacholine-induced cough but normal airway sensitivity using mannitol and high-dose methacholine bronchoprovocation testing.
NCT01064245 ↗ Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests Active, not recruiting The Ontario Thoracic Society of the Ontario Lung Association N/A 2010-02-01 Cough is a common, disruptive and at times disabling symptom which often prompts patients to seek medical attention. Determining the cause(s) of chronic cough can be challenging, and costly. Asthma and other airway disorders are among the most common causes of chronic cough; and cough can be the sole symptom of asthma. Little is known about why some patients with asthma primarily cough and do not develop the other symptoms of asthma such as shortness of breath or wheeze. Improved understanding of the reasons for these different manifestations may lead to new and more effective treatment strategies. We have notices differences in pressure measurements inside the chest in patients who mostly cough during induced bronchoconstriction, which might be part of the explanation for varying symptoms. This study will compare lung mechanical responses during methacholine and mannitol-induced induced airway narrowing between typical asthma, cough variant asthma (CVA) and an airway inflammatory disorder that is not asthma.The purpose of this research is to explore the pathophysiology and sensory-mechanics of cough in individuals with asthma, CVA and methacholine-induced cough but normal airway sensitivity using mannitol and high-dose methacholine bronchoprovocation testing.
NCT01064245 ↗ Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests Active, not recruiting Dr. Diane Lougheed N/A 2010-02-01 Cough is a common, disruptive and at times disabling symptom which often prompts patients to seek medical attention. Determining the cause(s) of chronic cough can be challenging, and costly. Asthma and other airway disorders are among the most common causes of chronic cough; and cough can be the sole symptom of asthma. Little is known about why some patients with asthma primarily cough and do not develop the other symptoms of asthma such as shortness of breath or wheeze. Improved understanding of the reasons for these different manifestations may lead to new and more effective treatment strategies. We have notices differences in pressure measurements inside the chest in patients who mostly cough during induced bronchoconstriction, which might be part of the explanation for varying symptoms. This study will compare lung mechanical responses during methacholine and mannitol-induced induced airway narrowing between typical asthma, cough variant asthma (CVA) and an airway inflammatory disorder that is not asthma.The purpose of this research is to explore the pathophysiology and sensory-mechanics of cough in individuals with asthma, CVA and methacholine-induced cough but normal airway sensitivity using mannitol and high-dose methacholine bronchoprovocation testing.
NCT01064245 ↗ Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests Active, not recruiting Queen's University N/A 2010-02-01 Cough is a common, disruptive and at times disabling symptom which often prompts patients to seek medical attention. Determining the cause(s) of chronic cough can be challenging, and costly. Asthma and other airway disorders are among the most common causes of chronic cough; and cough can be the sole symptom of asthma. Little is known about why some patients with asthma primarily cough and do not develop the other symptoms of asthma such as shortness of breath or wheeze. Improved understanding of the reasons for these different manifestations may lead to new and more effective treatment strategies. We have notices differences in pressure measurements inside the chest in patients who mostly cough during induced bronchoconstriction, which might be part of the explanation for varying symptoms. This study will compare lung mechanical responses during methacholine and mannitol-induced induced airway narrowing between typical asthma, cough variant asthma (CVA) and an airway inflammatory disorder that is not asthma.The purpose of this research is to explore the pathophysiology and sensory-mechanics of cough in individuals with asthma, CVA and methacholine-induced cough but normal airway sensitivity using mannitol and high-dose methacholine bronchoprovocation testing.
NCT01618929 ↗ Effects of Montelukast in Asthmatic Children With and Without Food Allergy Completed Merck Sharp & Dohme Corp. Phase 4 2013-03-01 - To search the effects of montelukast on the airway inflammation including FEV1%, FEV1%/FVC, the provocholine® (methacoline chloride powder for inhalation) challenge tests, the leukotriene levels in the exhaled breath condensate in asthmatic children with and without food allergy aged 6-18 years old. - To define the patient groups with good response to montelukast and to define the parameters which predict the good response.
NCT01618929 ↗ Effects of Montelukast in Asthmatic Children With and Without Food Allergy Completed Hacettepe University Phase 4 2013-03-01 - To search the effects of montelukast on the airway inflammation including FEV1%, FEV1%/FVC, the provocholine® (methacoline chloride powder for inhalation) challenge tests, the leukotriene levels in the exhaled breath condensate in asthmatic children with and without food allergy aged 6-18 years old. - To define the patient groups with good response to montelukast and to define the parameters which predict the good response.
NCT01642745 ↗ Mannitol (Aridol) and Methacholine (Provocholine) Responsiveness Completed University of Saskatchewan Phase 4 2011-11-01 The study will compare the airway responses to two bronchoconstricting agents, mannitol and methacholine.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PROVOCHOLINE

Condition Name

Condition Name for PROVOCHOLINE
Intervention Trials
Asthma 5
Cough Variant Asthma 2
Bronchial Asthma 1
Children 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PROVOCHOLINE
Intervention Trials
Asthma 4
Cough 2
Respiratory Aspiration 1
Hyperventilation 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PROVOCHOLINE

Trials by Country

Trials by Country for PROVOCHOLINE
Location Trials
Canada 6
Turkey 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PROVOCHOLINE

Clinical Trial Phase

Clinical Trial Phase for PROVOCHOLINE
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PROVOCHOLINE
Clinical Trial Phase Trials
Completed 4
Not yet recruiting 1
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PROVOCHOLINE

Sponsor Name

Sponsor Name for PROVOCHOLINE
Sponsor Trials
University of Saskatchewan 4
Dr. Diane Lougheed 2
Queen's University 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PROVOCHOLINE
Sponsor Trials
Other 11
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

PROVOCHOLINE Clinical Trials Update, Market Analysis, and Forecast (2026–2036)

Last updated: May 21, 2026

Provocholine’s current development and commercial trajectory cannot be summarized accurately because there is no verifiable basis in the provided prompt to identify the correct drug entity, active ingredient(s), sponsor, indication(s), route of administration, or FDA/regulatory status. Without those identifiers, any attempt to compile trial updates, enrollment milestones, endpoints, safety signals, or market projections would be incomplete and could conflate unrelated compounds with similar names.

Clinical trials update for Provocholine: What endpoints, phases, and recruiting status exist?

What is the latest Phase and trial status for Provocholine?

  • No verifiable clinical-trial registry mapping to “PROVOCHOLINE” is possible from the prompt alone.

Which studies are recruiting, active not recruiting, or completed?

  • No registries, NCT numbers, investigator sites, enrollment targets, or dates are available in the prompt.

What efficacy and safety endpoints are being reported for Provocholine?

  • No protocol endpoints, timepoints, or adverse-event profiles are available in the prompt.

Subtopic: How does Provocholine compare with similar agents in the same therapeutic area?

  • No therapeutic target, mechanism of action, or comparators are provided.

Subtopic: What’s the development timeline implied by Provocholine’s clinical milestones?

  • No IND filing, first-in-human date, interim readout schedule, or NDA/BLA submission timeline is available.

Market analysis for Provocholine: How big is the addressable market and who are competitors?

What is Provocholine’s indication-specific market size?

  • The prompt does not specify the indication, patient population, dosing regimen, or geography.

Which companies are developing or selling competing therapies for Provocholine’s target?

  • No mechanism, target, or branded/generic landscape is provided.

How does Provocholine’s pricing and reimbursement profile shape revenue forecasts?

  • No route (oral/IV/other), formulation, expected strength, course length, or payer category is provided.

Revenue projection for Provocholine: When will sales peak and what share is realistic?

Base case, bull case, bear case forecast

  • No verifiable inputs are available for:
    • probability of technical success by phase,
    • expected label language,
    • launch year,
    • uptake curves,
    • competitor dynamics,
    • pricing benchmarks.

What drivers most affect Provocholine’s commercialization outcome?

  • Indication, regulatory pathway, and clinical differentiation are not specified.

Regulatory pathway for Provocholine: What is the Orange Book or FDA approval status?

What is the FDA status of Provocholine (approved, under review, or investigational)?

  • The prompt does not identify:
    • any NDA/BLA number,
    • sponsor,
    • approval letter date,
    • review classification (standard or priority),
    • exclusivity basis.

What exclusivities or patent protections could affect market entry?

  • No Orange Book listings, listed patents, or exclusivity codes are available in the prompt.

Key Takeaways

  • Provocholine cannot be analyzed with required precision because the prompt provides no verifiable identifiers to map the drug to clinical-trial records, FDA/regulatory status, or a specific commercial product.
  • Clinical trial update, competitive landscape, and sales projection all require correct drug identification (active ingredient, sponsor, indication, and regulatory pathway), none of which is present.

FAQs

  1. What is Provocholine’s mechanism of action and intended indication?
  2. What NCT trials exist for Provocholine, and which are recruiting?
  3. Has Provocholine received any FDA designations (Fast Track, Breakthrough, Orphan)?
  4. What does Provocholine’s competitive set look like in the same therapeutic niche?
  5. What is the likely launch timeline and pricing benchmark for Provocholine?

References

  • No sources were provided or identifiable from the prompt.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.